Investors of Baxter International Inc. Can Step Forward in Securities Fraud Class Action

Rosen Law Firm Announces Class Action for Baxter International Inc. Investors

The Rosen Law Firm, a prominent global advocate for investor rights, has recently filed a significant class action lawsuit aimed at protecting the interests of shareholders of Baxter International Inc. (NYSE: BAX). This legal action pertains to all individuals who purchased Baxter's common stock within the stipulated timeframe from February 23, 2022, to July 30, 2025. If you fall within this category, it's crucial for you to understand your potential eligibility for compensation without incurring out-of-pocket expenses, thanks to a contingency fee arrangement.

Why Join the Class Action?

Joining the class action lawsuit provides an opportunity for investors who have suffered financial losses due to misleading statements made by the company regarding its product safety and efficacy. Investors who purchased shares during the aforementioned class period are considered part of this legal action. If you're interested in serving as a lead plaintiff, it's essential to act quickly; the deadline to file a motion with the court is December 15, 2025.

Details of the Case

The lawsuit accuses Baxter International of failing to disclose critical information about the Novum LVP (Large Volume Pump), a medical device that experienced severe malfunctions resulting in patient risks, including serious injuries or fatalities. Key allegations include:

1. Systemic Defects: The Novum LVP was reported to have systemic issues that caused significant operating failures, including underinfusion, overinfusion, and complete fluid non-delivery.
2. Awareness of Malfunctions: Baxter was allegedly made aware of multiple device failures, resulting in injuries and deaths connected to these defects.
3. Inadequate Remedial Measures: Attempts by Baxter to mitigate these issues through customer alerts were deemed insufficient and inadequate, failing to address the design flaws.
4. Customer Risks: As a result of these undisclosed risks, there was an increased chance that customers would be required to remove the Novum LVPs from service entirely, putting a halt to all new sales.
5. Misleading Statements: The lawsuit contends that Baxter’s statements regarding the safety, efficacy, and market prospects of the Novum LVP were materially false and misleading.

When the actual details regarding these defects came to light, many investors experienced significant financial losses, prompting the class action filing.

How to Join the Class Action

If you're a Baxter investor who purchased shares during the class period, you can join the lawsuit by visiting this link. Additionally, interested individuals can reach out directly to Phillip Kim, Esq. at 866-767-3653 or via email to obtain more information about the class action. Please note that no class has yet been certified; thus, you aren't represented by legal counsel unless you retain one.

Selecting Your Counsel

Selecting the right lawyer is pivotal, especially in cases that hinge on investor rights and securities class action litigation. The Rosen Law Firm boasts a solid track record in this area, having secured significant settlements for investors in the past. In 2017, they were recognized as the top firm for securities class action settlements, recovering hundreds of millions for their clients, and achieving notable successes in various other cases as well.

Conclusion

The class action against Baxter International Inc. offers a chance for affected investors to come forward and seek justice. Serving as a lead plaintiff can empower you alongside other investors facing similar challenges. Being proactive and staying informed is crucial in navigating this complex legal landscape. Follow Rosen Law Firm on LinkedIn, Twitter, or Facebook for further updates and information.